Pfizer plans to localize its production in Kazakhstan

This is a project for the localization of biotechnology drugs, which involves contract manufacturing on the basis of existing pharmaceutical production facilities in Kazakhstan
Author Avatar

The 78th session of the UN General Assembly was officially opened in New York. According to the data of SK-Pharmacy LLC, the delegation from Kazakhstan met with Pfizer’s regional president Patrick van der Loo.

The meeting was one of the steps in the implementation of the Memorandum of Cooperation with Pfizer, signed during the working visit of the President of Kazakhstan to New York in September 2022. The parties discussed topical issues of expanding the presence of the American company in Kazakhstan, including the possibility of jointly implementing projects in the field of vaccine production.

In particular, it is a project for the localization of biotechnology drugs, which involves contract manufacturing on the basis of existing pharmaceutical production facilities in Kazakhstan. Namely, the production of the 20-valent conjugate pneumococcal vaccine Prevenar-20 manufactured by Pfizer (USA, TNC).

A roadmap was signed with the Ministry of Health and the Ministry of Foreign Affairs of the Republic of Kazakhstan to implement the project to localize the production of the pneumococcal vaccine Prevenar-20 earlier this year during the visit of Pfizer’s regional head Ozgur Yaziyurt to Astana.





0.0
0.0 out of 5 stars (based on 0 reviews)
Excellent0%
Very good0%
Average0%
Poor0%
Terrible0%
Scroll to Top